The International Trade Commission is asking for comments by April 11 on public interest issues raised by ResMed’s Section 337 patent complaint on sleep-disordered breathing treatment systems and components (see 13040201). According to the underlying petition, the products are used in the treatment of obstructive sleep apnea by delivering pressurized air to the user to keep that user’s breathing passages open during sleep. ResMed alleges that Apex Medical and Drive Medical Design & Manufacturing manufacture and import breathing treatment systems that infringe its patents. ResMed is requesting cease and desist and limited exclusion orders against the respondents.
ResMed filed a Section 337 complaint with the International Trade Commission March 28, alleging imports of sleep-disordered breathing treatment systems and components from Apex Medical and Drive Medical Design & Manufacturing infringe its patents. The products are used in the treatment of obstructive sleep apnea by delivering pressurized air to the user to keep that user’s breathing passages open during sleep, the petition for investigation said. According to Resmed, Apex makes infringing breathing treatment systems abroad, and imports them into the U.S. through its affiliate Apex Medical USA. Medical Depot, which does business as Drive Medical Design & Manufacturing, also imports infringing breathing treatment systems it buys from Apex Medical, the complaint alleged. ResMed is requesting the ITC issue limited exclusion and cease and desist orders against the proposed respondents.
The International Trade Administration published notices in the April 2 Federal Register on the following AD/CV duty proceedings (any notices that announce changes to AD/CV duty rates, scope, affected firms, or effective dates will be detailed in another ITT article):
The International Trade Commission is publishing notices in the April 1 Federal Register on the following AD/CV injury, Section 337 patent, and other trade proceedings (any notices that warrant a more detailed summary will appear in another ITT article):
The International Trade Administration announced the opportunity to request administrative reviews by April 30 for producers and exporters subject to eight antidumping duty orders with April anniversary dates. Affected products include activated carbon, frontseating service valves, and magnesium metal.
The International Trade Administration and the International Trade Commission initiated the five-year Sunset Review of the antidumping and countervailing duty orders on light-walled rectangular pipe and tube from China, Korea, Mexico, and Turkey (A-570-914 / C-570-915, A-580-859, A-201-836, A-489-815); and the AD/CV duty orders on polyethylene terephthlate (PET) film from India and Taiwan (A-533-824 / C-533-825, A-583-837).
The International Trade Administration initiated administrative reviews for companies subject to the antidumping orders on frozen warmwater shrimp from India and Thailand. The ITA intends to issue the final results of these reviews by Feb. 28, 2014. The ITA published its notice initiating other antidumping and countervailing duty reviews in the March 29 Federal Register (see 13032816).
The International Trade Commission is publishing notices in the March 29 Federal Register on the following AD/CV injury, Section 337 patent, and other trade proceedings (any notices that warrant a more detailed summary will appear in another ITT article):
The International Trade Administration published notices in the March 29 Federal Register on the following AD/CV duty proceedings (any notices that announce changes to AD/CV duty rates, scope, affected firms, or effective dates will be detailed in another ITT article):
Thomas Steel Strip Corporation filed a petition March 27 requesting an antidumping duty investigation of diffusion-annealed, nickel-plated steel flat-rolled products from Japan (A-588-869). According to the petition, Japanese companies are dumping nickel-plated steel in the U.S. at rates from 37.7 to 73.5 percent less than their home market price levels.